BACKGROUND & AIMS: We studied the role of protease-activated receptor 2 (PAR(2)) and its activating enzymes, trypsins and tryptase, in Clostridium difficile toxin A (TxA)-induced enteritis. METHODS: We injected TxA into ileal loops in PAR(2) or dipeptidyl peptidase I (DPPI) knockout mice or in wild-type mice pretreated with tryptase inhibitors (FUT-175 or MPI-0442352) or soybean trypsin inhibitor. We examined the effect of TxA on expression and activity of PAR(2) and trypsin IV messenger RNA in the ileum and cultured colonocytes. We injected activating peptide (AP), trypsins, tryptase, and p23 in wild-type mice, some pretreated with the neurokinin 1 receptor antagonist SR140333. RESULTS: TxA increased fluid secretion, myeloperoxidase activity in fluid and tissue, and histologic damage. PAR(2) deletion decreased TxA-induced ileitis, reduced luminal fluid secretion by 20%, decreased tissue and fluid myeloperoxidase by 50%, and diminished epithelial damage, edema, and neutrophil infiltration. DPPI deletion reduced secretion by 20% and fluid myeloperoxidase by 55%. In wild-type mice, FUT-175 or MPI-0442352 inhibited secretion by 24%-28% and tissue and fluid myeloperoxidase by 31%-71%. Soybean trypsin inhibitor reduced secretion to background levels and tissue myeloperoxidase by up to 50%. TxA increased expression of PAR(2) and trypsin IV in enterocytes and colonocytes and caused a 2-fold increase in Ca(2+) responses to PAR(2) AP. AP, tryptase, and trypsin isozymes (trypsin I/II, trypsin IV, p23) caused ileitis. SR140333 prevented AP-induced ileitis. CONCLUSIONS: PAR(2) and its activators are proinflammatory in TxA-induced enteritis. TxA stimulates existing PAR(2) and up-regulates PAR(2) and activating proteases, and PAR(2) causes inflammation by neurogenic mechanisms.
BACKGROUND & AIMS: We studied the role of protease-activated receptor 2 (PAR(2)) and its activating enzymes, trypsins and tryptase, in Clostridium difficile toxin A (TxA)-induced enteritis. METHODS: We injected TxA into ileal loops in PAR(2) or dipeptidyl peptidase I (DPPI) knockout mice or in wild-type mice pretreated with tryptase inhibitors (FUT-175 or MPI-0442352) or soybean trypsin inhibitor. We examined the effect of TxA on expression and activity of PAR(2) and trypsin IV messenger RNA in the ileum and cultured colonocytes. We injected activating peptide (AP), trypsins, tryptase, and p23 in wild-type mice, some pretreated with the neurokinin 1 receptor antagonist SR140333. RESULTS:TxA increased fluid secretion, myeloperoxidase activity in fluid and tissue, and histologic damage. PAR(2) deletion decreased TxA-induced ileitis, reduced luminal fluid secretion by 20%, decreased tissue and fluid myeloperoxidase by 50%, and diminished epithelial damage, edema, and neutrophil infiltration. DPPI deletion reduced secretion by 20% and fluid myeloperoxidase by 55%. In wild-type mice, FUT-175 or MPI-0442352 inhibited secretion by 24%-28% and tissue and fluid myeloperoxidase by 31%-71%. Soybean trypsin inhibitor reduced secretion to background levels and tissue myeloperoxidase by up to 50%. TxA increased expression of PAR(2) and trypsin IV in enterocytes and colonocytes and caused a 2-fold increase in Ca(2+) responses to PAR(2) AP. AP, tryptase, and trypsin isozymes (trypsin I/II, trypsin IV, p23) caused ileitis. SR140333 prevented AP-induced ileitis. CONCLUSIONS:PAR(2) and its activators are proinflammatory in TxA-induced enteritis. TxA stimulates existing PAR(2) and up-regulates PAR(2) and activating proteases, and PAR(2) causes inflammation by neurogenic mechanisms.
Authors: M Steinhoff; N Vergnolle; S H Young; M Tognetto; S Amadesi; H S Ennes; M Trevisani; M D Hollenberg; J L Wallace; G H Caughey; S E Mitchell; L M Williams; P Geppetti; E A Mayer; N W Bunnett Journal: Nat Med Date: 2000-02 Impact factor: 53.440
Authors: K S Kirkwood; N W Bunnett; J Maa; I Castagliolo; B Liu; N Gerard; J Zacks; C Pothoulakis; E F Grady Journal: Am J Physiol Gastrointest Liver Physiol Date: 2001-08 Impact factor: 4.052
Authors: N Vergnolle; N W Bunnett; K A Sharkey; V Brussee; S J Compton; E F Grady; G Cirino; N Gerard; A I Basbaum; P Andrade-Gordon; M D Hollenberg; J L Wallace Journal: Nat Med Date: 2001-07 Impact factor: 53.440
Authors: C O Ogbu; M N Qabar; P D Boatman; J Urban; J P Meara; M D Ferguson; J Tulinsky; C Lum; S Babu; M A Blaskovich; H Nakanishi; F Ruan; B Cao; R Minarik; T Little; S Nelson; M Nguyen; A Gall; M Kahn Journal: Bioorg Med Chem Lett Date: 1998-09-08 Impact factor: 2.823
Authors: Jörg Buddenkotte; Christopher Stroh; Ingo H Engels; Corinna Moormann; Victoria M Shpacovitch; Stephan Seeliger; Nathalie Vergnolle; Dietmar Vestweber; Thomas A Luger; Klaus Schulze-Osthoff; Martin Steinhoff Journal: J Invest Dermatol Date: 2005-01 Impact factor: 8.551
Authors: I Castagliuolo; M Riegler; A Pasha; S Nikulasson; B Lu; C Gerard; N P Gerard; C Pothoulakis Journal: J Clin Invest Date: 1998-04-15 Impact factor: 14.808
Authors: I Castagliuolo; C C Wang; L Valenick; A Pasha; S Nikulasson; R E Carraway; C Pothoulakis Journal: J Clin Invest Date: 1999-03 Impact factor: 14.808
Authors: Jon Mallen-St Clair; Christine T N Pham; S Armando Villalta; George H Caughey; Paul J Wolters Journal: J Clin Invest Date: 2004-02 Impact factor: 14.808
Authors: Fiore Cattaruzza; Victoria Lyo; Ella Jones; David Pham; James Hawkins; Kimberley Kirkwood; Eduardo Valdez-Morales; Charles Ibeakanma; Stephen J Vanner; Matthew Bogyo; Nigel W Bunnett Journal: Gastroenterology Date: 2011-07-28 Impact factor: 22.682
Authors: T Shea-Donohue; L Notari; J Stiltz; R Sun; K B Madden; J F Urban; A Zhao Journal: Neurogastroenterol Motil Date: 2010-07-11 Impact factor: 3.598
Authors: Melinda A Engevik; Lori D Banks; Kristen A Engevik; Alexandra L Chang-Graham; Jacob L Perry; Diane S Hutchinson; Nadim J Ajami; Joseph F Petrosino; Joseph M Hyser Journal: Gut Microbes Date: 2020-05-13